Axitinib | AG-013736 | 阿西替尼 | VEGFR | PDGFR | c-Kit

首页 / 抑制剂/激动剂 / / / Axitinib

阿昔替尼 /Axitinib 98%

货号：A226761 同义名： 阿西替尼 / AG-013736 产品仅供科研

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Axitinib 化学结构
CAS号：319460-85-0

Axitinib 3D分子结构
CAS号：319460-85-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费分装

免费溶解
下载资料

Axitinib 纯度/质量文件

货号：A226761 标准纯度：98% 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Mar. Drugs, 2024, 22(5): 194. Ambeed. [ A104599 ]; • Pharmaceuticals, 2024, 17(5): 570. Ambeed. [ A224421 ]; 更多 >

c-Kit 亚型比较
PDGFR 亚型比较
VEGFR 亚型比较

产品名称	c-Kit ↓ ↑	其他靶点	纯度
Tyrphostin AG1296	+ c-Kit (Swiss 3T3), IC50: 1.8 μM	PDGFR	99%+
Masitinib	+ Kit, IC50: 200 nM		99%+
Motesanib Diphosphate	+++ Kit, IC50: 8 nM		99%+
Ki8751	++ c-Kit, IC50: 40 nM		98+%
Tivozanib	++ c-Kit, IC50: 78 nM		99%+
Pazopanib	+ c-Kit, IC50: 140 nM		99%
Sitravatinib	+++ Kit, IC50: 6 nM		99%+
Pexidartinib	+++ Kit, IC50: 10 nM		99%+
Lactate	++++ c-Kit, IC50: 2 nM	FLT3	85%
Amuvatinib	+++ c-Kit (D816H), IC50: 10 nM		99%+
Imatinib Mesylate	+ c-Kit, IC50: 100 nM	PDGFR	99%
AZD2932	+++ c-Kit, IC50: 9 nM		98%
Axitinib	++++ Kit, IC50: 1.7 nM		98%
Dovitinib	++++ c-Kit, IC50: 2 nM	FLT3	99%+
Sunitinib	✔	FLT3	98%
OSI-930	+ Kit, IC50: 80 nM		99%+
Telatinib	++++ c-Kit, IC50: 1 nM		99%+
Dasatinib monohydrate	++ c-Kit (wt), IC50: 79 nM c-Kit (D816V), IC50: 37 nM	Src	98%
Dasatinib	++ c-Kit (wt), IC50: 79 nM c-Kit (D816V), IC50: 37 nM	Src	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	PDGFR ↓ ↑	PDGFRα ↓ ↑	PDGFRβ ↓ ↑	其他靶点	纯度
Tyrphostin A9	+ PDGFR, IC50: 0.5 μM			EGFR	98%
Tyrphostin AG1296					99%+
Motesanib Diphosphate	++ PDGFR, IC50: 84 nM				99%+
Pazopanib	++ PDGFR, IC50: 84 nM				99%
Imatinib	+ PDGFR, IC50: 100 nM			c-Kit	98%
Imatinib Mesylate	+ PDGFR, IC50: 100 nM			c-Kit	99%
Sennoside B	✔				99%+
PP121	++++ PDGFR, IC50: 2 nM			mTOR,VEGFR	99%+
Crenolanib		++++ PDGFRα, Kd: 2.1 nM	++++ PDGFRβ, Kd: 3.2 nM		99%+
Masitinib		+ PDGFRα, IC50: 540 nM	+ PDGFRβ, IC50: 800 nM		99%+
Ki8751		++ PDGFRα, IC50: 67 nM		c-Kit	98+%
Tivozanib		++ PDGFRα, IC50: 40 nM	++ PDGFRβ, IC50: 49 nM		99%+
Ponatinib		++++ PDGFRα, IC50: 1.1 nM			98%
Amuvatinib		++ PDGFRα (V561D), IC50: 40 nM			99%+
Axitinib		+++ PDGFRα, IC50: 5.0 nM	++++ PDGFRβ, IC50: 1.6 nM		98%
CP-673451		+++ PDGFRα, IC50: 10 nM	++++ PDGFRβ, IC50: 1 nM		99%+
Telatinib		+++ PDGFRα, IC50: 15 nM		c-Kit	99%+
Nintedanib		++ PDGFRα, IC50: 59 nM	++ PDGFRβ, IC50: 65 nM		99+%
Avapritinib		++++ PDGFRα (D842V), IC50: 0.5 nM			99%+
MK-2461			+++ PDGFRβ, IC50: 22 nM		99%+
Lactate			+++ PDGFRβ, IC50: 27 nM	c-Kit,FLT3	85%
Linifanib			++ PDGFRβ, IC50: 66 nM		99%+
AZD2932			+++ PDGFRβ, IC50: 4 nM	c-Kit	98%
Dovitinib			+++ PDGFRβ, IC50: 27 nM	c-Kit,FLT3	99%+
Sorafenib			++ mPDGFRβ, IC50: 57 nM PDGFRβ, IC50: 57 nM		99%
Sunitinib			++++ PDGFRβ , IC50: 2 nM	FLT3	98%
Orantinib			+++ PDGFRβ, Ki: 8 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	PDGFR,RET	99%+
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	PDGFR,c-Kit,FGFR	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	99%+
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		98%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			98%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	98+%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	98%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			99%+
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	98%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Axitinib 生物活性

靶点

c-Kit

Kit, IC50:1.7 nM
VEGFR1

VEGFR1/FLT1, IC50:0.1 nM
VEGFR1

VEGFR1/FLT1, IC50:0.1 nM
VEGFR3

VEGFR3, IC50:0.1 nM-0.3 nM

描述

VEGF/VEGFR (vascular endothelial growth factor/vascular endothelial growth factor receptor) pathway plays a key role in tumor angiogenesis by promotion of vascular and lymphatic endothelial, as well as survival, and invasion, thus resulting in neovascularization, tumor growth and metastasis. Axitinib is a selective and potent VEGFR inhibitor with IC50 values of 0.1nM, 0.18nM, 0.2nM and 0.1nM-0.3nM for VEGFR1/FLT1, VEGFR2/Flk1, VEGFR2/KDR and VEGFR3, as well as less potent to PDGFRβ, Kit and PDGFRα with IC50 value of 1.6nM, 1.7nM and 5.0nM (measured by enzymatic assays), respectively. Treatment with Axitinib at concentration ranging in 1-300nM for 45min caused inhibition on downstream signaling induced by VEGF (50ng/ml), including p-AKT (>1nM), p-eNOS (>1nM) and p-ERK (>10nM), in a dose-dependent manner in HUVECs. Axitinib inhibited dose dependently VEGF-stimulated (20ng/ml) growth of HUVECs (for 3 days) with IC50 of 0.17nM, as well as blocked the sprouting and tube formation of human microvascular endothelial cell spheroids at 3, 6, 12.5, 25, and 50nM (for 7 days). Oral treatment with Axitinib at dose ranging in 3-150mg/kg showed dose-dependently tumor growth inhibition in MV522 tumor model, with reduced Ki-67 (marked cell division) and increased caspase-3 in the tumor. Axitinib also enhanced antitumor efficacy of chemotherapeutic agents, including docetaxel in LLC and human breast cancer models, carboplatin in a human ovarian cancer model and gemcitabine in a human pancreatic cancer model, as well as produced significant antimetastasis activity combined with bevacizumab in M24met model^[1].

Axitinib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
22RV1		Growth Inhibition Assay		IC50=17.5884 μM	SANGER
23132-87		Growth Inhibition Assay		IC50=12.0821 μM	SANGER
5637		Growth Inhibition Assay		IC50=29.6421 μM	SANGER
697		Growth Inhibition Assay		IC50=14.627 μM	SANGER

Axitinib 动物研究

Dose	Mice: min = 25 mg/kg^[2], max = 35 mg/kg^[3]
Administration	p.o., i.p.

Axitinib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00692341	Hepatic Insufficiency	Phase 1	Completed	-	United States, Florida ... 展开 >> Pfizer Investigational Site Miami, Florida, United States, 33169 Pfizer Investigational Site Orlando, Florida, United States, 32809 收起 <<
NCT03386929	Non-small Cell Lung Cancer Met... 展开 >>astatic Non-Small Cell Lung Cancer Stage IIIB 收起 <<	Phase 1 Phase 2	Recruiting	December 2022	United States, California ... 展开 >> UCSD Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Sarah MOORE sam055@ucsd.edu Principal Investigator: Lyudmila BAZHENOVA, MD United States, South Dakota Avera Cancer Center Recruiting Sioux Falls, South Dakota, United States, 57105 Contact: Martha LANG Martha.lang@avera.org Principal Investigator: Benjamin SOLOMON, MD France Centre Léon Bérard Recruiting Lyon, France, 69008 Contact: Séverine LAURENT severine.laurent@lyon.unicancer.fr Principal Investigator: Pierre SAINTIGNY, MD Israel Chiam Sheba Medical Center Recruiting Ramat Gan, Israel, 5265601 Contact: Yona GILADY yona.gilady@sheba.health.gov.il Principal Investigator: Jair BAR, MD Luxembourg Centre Hospitalier Luxembourg Recruiting Luxembourg, Luxembourg, 1210 Contact: Lucile PERNOT lucile.pernot@lih.lu Principal Investigator: Guy BERCHEM, MD Spain Vall Hebron Institute of Oncology Recruiting Barcelona, Spain, 08035 Contact: LLuisa CARBONELL llcarbonell@vhio.net Principal Investigator: Enriqueta Felip, MD 收起 <<
NCT00389441	Thyroid Neoplasms	Phase 2	Completed	-	-

Axitinib 参考文献

[1]Hu-Lowe DD, Zou HY, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14(22):7272-83.

[2]Du Four S, Maenhout SK, et al. Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology. 2015;4(4):e998107.

[3]Van der Veken B, De Meyer GRY, Martinet W. Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice. Vascul Pharmacol. 2018.

Axitinib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.59mL

0.52mL

0.26mL

12.94mL

2.59mL

1.29mL

25.88mL

5.17mL

2.59mL

Axitinib 技术信息

CAS号	319460-85-0
分子式	C₂₂H₁₈N₄OS
分子量	386.469

别名	阿西替尼 ;AG-013736
运输	蓝冰

存储条件

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 20 mg/mL(51.75 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 1.5 mg/mL clear

PO 0.5% CMC-Na 60 mg/mL suspension

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

c-Kit	Kit, IC50:1.7 nM
VEGFR1	VEGFR1/FLT1, IC50:0.1 nM
VEGFR1	VEGFR1/FLT1, IC50:0.1 nM
VEGFR3	VEGFR3, IC50:0.1 nM-0.3 nM
VEGFR3	VEGFR3, IC50:0.1 nM-0.3 nM
PDGFRα	PDGFRα, IC50:5.0 nM
PDGFRα	PDGFRα, IC50:5.0 nM
VEGFR2	VEGFR2/KDR, IC50:0.2 nM VEGFR2/Flk1, IC50:0.18 nM
VEGFR2	VEGFR2/KDR, IC50:0.2 nM VEGFR2/Flk1, IC50:0.18 nM
PDGFRβ	PDGFRβ, IC50:1.6 nM
PDGFRβ	PDGFRβ, IC50:1.6 nM

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源

22RV1	Growth Inhibition Assay	IC50=17.5884 μM	SANGER
23132-87	Growth Inhibition Assay	IC50=12.0821 μM	SANGER
5637	Growth Inhibition Assay	IC50=29.6421 μM	SANGER
697	Growth Inhibition Assay	IC50=14.627 μM	SANGER
786-0	Growth Inhibition Assay	IC50=37.2794 μM	SANGER
8305C	Growth Inhibition Assay	IC50=16.7877 μM	SANGER
8505C	Growth Inhibition Assay	IC50=8.64824 μM	SANGER
8-MG-BA	Growth Inhibition Assay	IC50=4.26658 μM	SANGER
A101D	Growth Inhibition Assay	IC50=13.5349 μM	SANGER
A172	Growth Inhibition Assay	IC50=2.13606 μM	SANGER
A204	Growth Inhibition Assay	IC50=0.00992 μM	SANGER
A2058	Growth Inhibition Assay	IC50=31.1164 μM	SANGER
A2780	Growth Inhibition Assay	IC50=1.01146 μM	SANGER
A375	Growth Inhibition Assay	IC50=31.1696 μM	SANGER
A3-KAW	Growth Inhibition Assay	IC50=4.97352 μM	SANGER
A427	Growth Inhibition Assay	IC50=1.10381 μM	SANGER
A431	Growth Inhibition Assay	IC50=47.8338 μM	SANGER
A498	Growth Inhibition Assay	IC50=41.3015 μM	SANGER
A4-Fuk	Growth Inhibition Assay	IC50=2.47168 μM	SANGER
A549	Growth Inhibition Assay	IC50=12.3285 μM	SANGER
A673	Growth Inhibition Assay	IC50=27.2102 μM	SANGER
A704	Growth Inhibition Assay	IC50=6.10574 μM	SANGER
ABC-1	Growth Inhibition Assay	IC50=3.93911 μM	SANGER
ACN	Growth Inhibition Assay	IC50=2.23875 μM	SANGER
AGS	Growth Inhibition Assay	IC50=1.11395 μM	SANGER
ALL-PO	Growth Inhibition Assay	IC50=1.80015 μM	SANGER
AN3-CA	Growth Inhibition Assay	IC50=1.08389 μM	SANGER
AsPC-1	Growth Inhibition Assay	IC50=30.0212 μM	SANGER
ATN-1	Growth Inhibition Assay	IC50=22.6439 μM	SANGER
AU565	Growth Inhibition Assay	IC50=17.225 μM	SANGER
BB65-RCC	Growth Inhibition Assay	IC50=20.9285 μM	SANGER
BE-13	Growth Inhibition Assay	IC50=0.51008 μM	SANGER
Becker	Growth Inhibition Assay	IC50=9.41944 μM	SANGER
BFTC-905	Growth Inhibition Assay	IC50=33.5136 μM	SANGER
BHT-101	Growth Inhibition Assay	IC50=29.321 μM	SANGER
BPH-1	Growth Inhibition Assay	IC50=46.9805 μM	SANGER
BT-549	Growth Inhibition Assay	IC50=1.56909 μM	SANGER
BV-173	Growth Inhibition Assay	IC50=0.3932 μM	SANGER
C2BBe1	Growth Inhibition Assay	IC50=40.9157 μM	SANGER
C32	Growth Inhibition Assay	IC50=32.3353 μM	SANGER
C8166	Growth Inhibition Assay	IC50=49.2039 μM	SANGER
Ca9-22	Growth Inhibition Assay	IC50=10.0665 μM	SANGER
CAKI-1	Growth Inhibition Assay	IC50=30.7702 μM	SANGER
CAL-12T	Growth Inhibition Assay	IC50=10.6361 μM	SANGER
CAL-27	Growth Inhibition Assay	IC50=4.24344 μM	SANGER
CAL-51	Growth Inhibition Assay	IC50=43.5605 μM	SANGER
CAL-54	Growth Inhibition Assay	IC50=29.5445 μM	SANGER
CAL-72	Growth Inhibition Assay	IC50=49.6075 μM	SANGER
CAMA-1	Growth Inhibition Assay	IC50=28.8564 μM	SANGER
CaR-1	Growth Inhibition Assay	IC50=16.8111 μM	SANGER
CAS-1	Growth Inhibition Assay	IC50=4.99908 μM	SANGER
Ca-Ski	Growth Inhibition Assay	IC50=29.946 μM	SANGER
CFPAC-1	Growth Inhibition Assay	IC50=43.4944 μM	SANGER
CGTH-W-1	Growth Inhibition Assay	IC50=0.00722 μM	SANGER
ChaGo-K-1	Growth Inhibition Assay	IC50=4.89048 μM	SANGER
CHL-1	Growth Inhibition Assay	IC50=17.9249 μM	SANGER
CHP-212	Growth Inhibition Assay	IC50=2.82091 μM	SANGER
COLO-320-HSR	Growth Inhibition Assay	IC50=9.60237 μM	SANGER
COLO-684	Growth Inhibition Assay	IC50=13.4541 μM	SANGER
COLO-800	Growth Inhibition Assay	IC50=7.94492 μM	SANGER
COLO-829	Growth Inhibition Assay	IC50=5.91504 μM	SANGER
COR-L105	Growth Inhibition Assay	IC50=3.63334 μM	SANGER
COR-L23	Growth Inhibition Assay	IC50=18.0011 μM	SANGER
COR-L88	Growth Inhibition Assay	IC50=23.9475 μM	SANGER
CP50-MEL-B	Growth Inhibition Assay	IC50=20.4748 μM	SANGER
CTB-1	Growth Inhibition Assay	IC50=9.01433 μM	SANGER
CTV-1	Growth Inhibition Assay	IC50=22.3031 μM	SANGER
D-247MG	Growth Inhibition Assay	IC50=16.8625 μM	SANGER
D-263MG	Growth Inhibition Assay	IC50=9.83384 μM	SANGER
D-283MED	Growth Inhibition Assay	IC50=9.63072 μM	SANGER
D-392MG	Growth Inhibition Assay	IC50=5.57849 μM	SANGER
D-423MG	Growth Inhibition Assay	IC50=8.2172 μM	SANGER
D-502MG	Growth Inhibition Assay	IC50=6.28857 μM	SANGER
D-542MG	Growth Inhibition Assay	IC50=22.5558 μM	SANGER
D-566MG	Growth Inhibition Assay	IC50=1.40683 μM	SANGER
Daoy	Growth Inhibition Assay	IC50=17.7184 μM	SANGER
DB	Growth Inhibition Assay	IC50=13.9928 μM	SANGER
DEL	Growth Inhibition Assay	IC50=1.25457 μM	SANGER
Detroit562	Growth Inhibition Assay	IC50=40.1268 μM	SANGER
DK-MG	Growth Inhibition Assay	IC50=2.23834 μM	SANGER
DMS-114	Growth Inhibition Assay	IC50=2.66345 μM	SANGER
DMS-273	Growth Inhibition Assay	IC50=2.90207 μM	SANGER
DOHH-2	Growth Inhibition Assay	IC50=20.906 μM	SANGER
DOK	Growth Inhibition Assay	IC50=14.9933 μM	SANGER
DU-145	Growth Inhibition Assay	IC50=4.12825 μM	SANGER
EC-GI-10	Growth Inhibition Assay	IC50=43.8347 μM	SANGER
EFM-19	Growth Inhibition Assay	IC50=5.41737 μM	SANGER
EGI-1	Growth Inhibition Assay	IC50=21.7454 μM	SANGER
EM-2	Growth Inhibition Assay	IC50=0.16816 μM	SANGER
EoL-1-cell	Growth Inhibition Assay	IC50=0.0000513 μM	SANGER
EPLC-272H	Growth Inhibition Assay	IC50=19.3708 μM	SANGER
ES1	Growth Inhibition Assay	IC50=3.83094 μM	SANGER
ES3	Growth Inhibition Assay	IC50=18.5883 μM	SANGER
ES4	Growth Inhibition Assay	IC50=29.3172 μM	SANGER
ES5	Growth Inhibition Assay	IC50=1.17248 μM	SANGER
ES6	Growth Inhibition Assay	IC50=11.8581 μM	SANGER
ES7	Growth Inhibition Assay	IC50=1.11334 μM	SANGER
ES8	Growth Inhibition Assay	IC50=3.34999 μM	SANGER
ESS-1	Growth Inhibition Assay	IC50=23.8059 μM	SANGER
ETK-1	Growth Inhibition Assay	IC50=13.0779 μM	SANGER
EW-1	Growth Inhibition Assay	IC50=4.53014 μM	SANGER
EW-11	Growth Inhibition Assay	IC50=3.63022 μM	SANGER
EW-13	Growth Inhibition Assay	IC50=32.9408 μM	SANGER
EW-16	Growth Inhibition Assay	IC50=5.75583 μM	SANGER
EW-22	Growth Inhibition Assay	IC50=36.4072 μM	SANGER
G-361	Growth Inhibition Assay	IC50=0.32325 μM	SANGER
G-402	Growth Inhibition Assay	IC50=1.14694 μM	SANGER
GCT	Growth Inhibition Assay	IC50=2.00916 μM	SANGER
GI-1	Growth Inhibition Assay	IC50=10.3533 μM	SANGER
GI-ME-N	Growth Inhibition Assay	IC50=7.64934 μM	SANGER
GOTO	Growth Inhibition Assay	IC50=2.53013 μM	SANGER
GP5d	Growth Inhibition Assay	IC50=16.342 μM	SANGER
GT3TKB	Growth Inhibition Assay	IC50=16.0676 μM	SANGER
H4	Growth Inhibition Assay	IC50=1.06422 μM	SANGER
H9	Growth Inhibition Assay	IC50=12.5577 μM	SANGER
HAL-01	Growth Inhibition Assay	IC50=7.60644 μM	SANGER
HC-1	Growth Inhibition Assay	IC50=32.1446 μM	SANGER
HCC1187	Growth Inhibition Assay	IC50=4.21597 μM	SANGER
HCC1395	Growth Inhibition Assay	IC50=3.99484 μM	SANGER
HCC1419	Growth Inhibition Assay	IC50=7.53 μM	SANGER
HCC1569	Growth Inhibition Assay	IC50=6.53737 μM	SANGER
HCC1806	Growth Inhibition Assay	IC50=3.27657 μM	SANGER
HCC1937	Growth Inhibition Assay	IC50=24.1 μM	SANGER
HCC2998	Growth Inhibition Assay	IC50=7.60743 μM	SANGER
HCC38	Growth Inhibition Assay	IC50=24.2394 μM	SANGER
HCE-T	Growth Inhibition Assay	IC50=2.20598 μM	SANGER
HCT-15	Growth Inhibition Assay	IC50=40.5907 μM	SANGER
HDLM-2	Growth Inhibition Assay	IC50=23.1478 μM	SANGER
HD-MY-Z	Growth Inhibition Assay	IC50=1.86281 μM	SANGER
HEC-1	Growth Inhibition Assay	IC50=8.78439 μM	SANGER
HEL	Growth Inhibition Assay	IC50=49.4064 μM	SANGER
H-EMC-SS	Growth Inhibition Assay	IC50=0.11005 μM	SANGER
HGC-27	Growth Inhibition Assay	IC50=4.2966 μM	SANGER
HH	Growth Inhibition Assay	IC50=26.5529 μM	SANGER
HL-60	Growth Inhibition Assay	IC50=20.2141 μM	SANGER
HLE	Growth Inhibition Assay	IC50=9.90909 μM	SANGER
HMV-II	Growth Inhibition Assay	IC50=1.70488 μM	SANGER
HN	Growth Inhibition Assay	IC50=40.1782 μM	SANGER
HO-1-N-1	Growth Inhibition Assay	IC50=11.3398 μM	SANGER
HOP-62	Growth Inhibition Assay	IC50=0.10836 μM	SANGER
HOS	Growth Inhibition Assay	IC50=4.6977 μM	SANGER
Hs-578-T	Growth Inhibition Assay	IC50=4.31468 μM	SANGER
HSC-2	Growth Inhibition Assay	IC50=44.009 μM	SANGER
HSC-3	Growth Inhibition Assay	IC50=12.9276 μM	SANGER
HSC-4	Growth Inhibition Assay	IC50=1.93839 μM	SANGER
HT-1080	Growth Inhibition Assay	IC50=37.125 μM	SANGER
HT-1197	Growth Inhibition Assay	IC50=14.0809 μM	SANGER
HT-144	Growth Inhibition Assay	IC50=17.6598 μM	SANGER
HuH-7	Growth Inhibition Assay	IC50=2.42165 μM	SANGER
HuO9	Growth Inhibition Assay	IC50=17.7031 μM	SANGER
HuP-T4	Growth Inhibition Assay	IC50=11.0328 μM	SANGER
HUTU-80	Growth Inhibition Assay	IC50=6.41688 μM	SANGER
IA-LM	Growth Inhibition Assay	IC50=7.68613 μM	SANGER
IGR-1	Growth Inhibition Assay	IC50=36.8184 μM	SANGER
IGROV-1	Growth Inhibition Assay	IC50=7.32386 μM	SANGER
J82	Growth Inhibition Assay	IC50=17.9635 μM	SANGER
JAR	Growth Inhibition Assay	IC50=0.23989 μM	SANGER
JEG-3	Growth Inhibition Assay	IC50=4.15916 μM	SANGER
J-RT3-T3-5	Growth Inhibition Assay	IC50=6.54572 μM	SANGER
JVM-3	Growth Inhibition Assay	IC50=5.72325 μM	SANGER
K5	Growth Inhibition Assay	IC50=0.42127 μM	SANGER
K-562	Growth Inhibition Assay	IC50=11.7248 μM	SANGER
KARPAS-45	Growth Inhibition Assay	IC50=5.84325 μM	SANGER
KASUMI-1	Growth Inhibition Assay	IC50=0.00682 μM	SANGER
KE-37	Growth Inhibition Assay	IC50=13.5887 μM	SANGER
KG-1	Growth Inhibition Assay	IC50=0.37642 μM	SANGER
KINGS-1	Growth Inhibition Assay	IC50=20.7967 μM	SANGER
KM12	Growth Inhibition Assay	IC50=5.29827 μM	SANGER
KM-H2	Growth Inhibition Assay	IC50=5.92395 μM	SANGER
KMOE-2	Growth Inhibition Assay	IC50=3.91808 μM	SANGER
KNS-81-FD	Growth Inhibition Assay	IC50=45.7365 μM	SANGER
KOSC-2	Growth Inhibition Assay	IC50=42.2699 μM	SANGER
KP-4	Growth Inhibition Assay	IC50=29.516 μM	SANGER
KP-N-YS	Growth Inhibition Assay	IC50=7.2072 μM	SANGER
KS-1	Growth Inhibition Assay	IC50=10.6301 μM	SANGER
KU812	Growth Inhibition Assay	IC50=0.16577 μM	SANGER
KY821	Growth Inhibition Assay	IC50=21.582 μM	SANGER
KYSE-510	Growth Inhibition Assay	IC50=35.5042 μM	SANGER
L-363	Growth Inhibition Assay	IC50=2.28061 μM	SANGER
L-428	Growth Inhibition Assay	IC50=30.405 μM	SANGER
LAMA-84	Growth Inhibition Assay	IC50=0.17665 μM	SANGER
LAN-6	Growth Inhibition Assay	IC50=37.9582 μM	SANGER
LB1047-RCC	Growth Inhibition Assay	IC50=4.81418 μM	SANGER
LB2241-RCC	Growth Inhibition Assay	IC50=39.8205 μM	SANGER
LB373-MEL-D	Growth Inhibition Assay	IC50=32.1971 μM	SANGER
LB771-HNC	Growth Inhibition Assay	IC50=12.765 μM	SANGER
LC-2-ad	Growth Inhibition Assay	IC50=4.22177 μM	SANGER
LCLC-103H	Growth Inhibition Assay	IC50=22.4752 μM	SANGER
LK-2	Growth Inhibition Assay	IC50=15.6449 μM	SANGER
LNCaP-Clone-FGC	Growth Inhibition Assay	IC50=34.8515 μM	SANGER
LoVo	Growth Inhibition Assay	IC50=16.9488 μM	SANGER
LOXIMVI	Growth Inhibition Assay	IC50=6.11248 μM	SANGER
LS-411N	Growth Inhibition Assay	IC50=26.2038 μM	SANGER
LU-135	Growth Inhibition Assay	IC50=33.801 μM	SANGER
LXF-289	Growth Inhibition Assay	IC50=1.43996 μM	SANGER
M14	Growth Inhibition Assay	IC50=37.1642 μM	SANGER
MCF7	Growth Inhibition Assay	IC50=46.5533 μM	SANGER
MC-IXC	Growth Inhibition Assay	IC50=29.2366 μM	SANGER
MDA-MB-231	Growth Inhibition Assay	IC50=18.6502 μM	SANGER
MDA-MB-361	Growth Inhibition Assay	IC50=10.4432 μM	SANGER
MDA-MB-415	Growth Inhibition Assay	IC50=7.89186 μM	SANGER
ME-180	Growth Inhibition Assay	IC50=31.6542 μM	SANGER
MEG-01	Growth Inhibition Assay	IC50=0.42361 μM	SANGER
MEL-JUSO	Growth Inhibition Assay	IC50=9.90127 μM	SANGER
MFM-223	Growth Inhibition Assay	IC50=0.44776 μM	SANGER
MHH-NB-11	Growth Inhibition Assay	IC50=2.70299 μM	SANGER
MHH-PREB-1	Growth Inhibition Assay	IC50=18.5697 μM	SANGER
MIA-PaCa-2	Growth Inhibition Assay	IC50=36.0496 μM	SANGER
MKN1	Growth Inhibition Assay	IC50=47.5137 μM	SANGER
MKN45	Growth Inhibition Assay	IC50=6.26016 μM	SANGER
ML-2	Growth Inhibition Assay	IC50=45.2621 μM	SANGER
MN-60	Growth Inhibition Assay	IC50=19.0592 μM	SANGER
MOLT-13	Growth Inhibition Assay	IC50=19.4546 μM	SANGER
MOLT-16	Growth Inhibition Assay	IC50=29.7269 μM	SANGER
MOLT-4	Growth Inhibition Assay	IC50=11.5985 μM	SANGER
Mo-T	Growth Inhibition Assay	IC50=42.8958 μM	SANGER
MS-1	Growth Inhibition Assay	IC50=35.3038 μM	SANGER
MSTO-211H	Growth Inhibition Assay	IC50=30.15 μM	SANGER
MV-4-11	Growth Inhibition Assay	IC50=2.59169 μM	SANGER
MZ2-MEL	Growth Inhibition Assay	IC50=37.4501 μM	SANGER
NB10	Growth Inhibition Assay	IC50=1.32557 μM	SANGER
NB12	Growth Inhibition Assay	IC50=21.0394 μM	SANGER
NB13	Growth Inhibition Assay	IC50=25.2611 μM	SANGER
NB14	Growth Inhibition Assay	IC50=1.01801 μM	SANGER
NB17	Growth Inhibition Assay	IC50=9.1887 μM	SANGER
NB6	Growth Inhibition Assay	IC50=46.111 μM	SANGER
NB7	Growth Inhibition Assay	IC50=16.6971 μM	SANGER
NBsusSR	Growth Inhibition Assay	IC50=5.03514 μM	SANGER
NCI-H1048	Growth Inhibition Assay	IC50=6.10599 μM	SANGER
NCI-H1092	Growth Inhibition Assay	IC50=35.2747 μM	SANGER
NCI-H1155	Growth Inhibition Assay	IC50=5.38185 μM	SANGER
NCI-H1299	Growth Inhibition Assay	IC50=33.5621 μM	SANGER
NCI-H1563	Growth Inhibition Assay	IC50=3.15005 μM	SANGER
NCI-H1573	Growth Inhibition Assay	IC50=23.4681 μM	SANGER
NCI-H1581	Growth Inhibition Assay	IC50=1.39042 μM	SANGER
NCI-H1648	Growth Inhibition Assay	IC50=30.5574 μM	SANGER
NCI-H1703	Growth Inhibition Assay	IC50=0.000902 μM	SANGER
NCI-H1770	Growth Inhibition Assay	IC50=18.4615 μM	SANGER
NCI-H1792	Growth Inhibition Assay	IC50=41.9821 μM	SANGER
NCI-H1793	Growth Inhibition Assay	IC50=35.6545 μM	SANGER
NCI-H2009	Growth Inhibition Assay	IC50=15.5095 μM	SANGER
NCI-H2029	Growth Inhibition Assay	IC50=15.3602 μM	SANGER
NCI-H2052	Growth Inhibition Assay	IC50=27.086 μM	SANGER
NCI-H209	Growth Inhibition Assay	IC50=31.8247 μM	SANGER
NCI-H2122	Growth Inhibition Assay	IC50=33.9966 μM	SANGER
NCI-H2228	Growth Inhibition Assay	IC50=8.15783 μM	SANGER
NCI-H226	Growth Inhibition Assay	IC50=13.8808 μM	SANGER
NCI-H23	Growth Inhibition Assay	IC50=12.5026 μM	SANGER
NCI-H2405	Growth Inhibition Assay	IC50=17.1908 μM	SANGER
NCI-H2452	Growth Inhibition Assay	IC50=28.0822 μM	SANGER
NCI-H28	Growth Inhibition Assay	IC50=5.87918 μM	SANGER
NCI-H292	Growth Inhibition Assay	IC50=1.66383 μM	SANGER
NCI-H358	Growth Inhibition Assay	IC50=11.2657 μM	SANGER
NCI-H446	Growth Inhibition Assay	IC50=3.22805 μM	SANGER
NCI-H460	Growth Inhibition Assay	IC50=16.7326 μM	SANGER
NCI-H510A	Growth Inhibition Assay	IC50=37.9412 μM	SANGER
NCI-H520	Growth Inhibition Assay	IC50=23.4948 μM	SANGER
NCI-H526	Growth Inhibition Assay	IC50=3.99126 μM	SANGER
NCI-H661	Growth Inhibition Assay	IC50=15.9075 μM	SANGER
NCI-H720	Growth Inhibition Assay	IC50=7.19345 μM	SANGER
NCI-H810	Growth Inhibition Assay	IC50=26.3112 μM	SANGER
NCI-H82	Growth Inhibition Assay	IC50=5.92771 μM	SANGER
NCI-SNU-1	Growth Inhibition Assay	IC50=26.5454 μM	SANGER
NEC8	Growth Inhibition Assay	IC50=0.72113 μM	SANGER
NH-12	Growth Inhibition Assay	IC50=11.5378 μM	SANGER
NKM-1	Growth Inhibition Assay	IC50=1.60556 μM	SANGER
NOMO-1	Growth Inhibition Assay	IC50=27.8532 μM	SANGER
NOS-1	Growth Inhibition Assay	IC50=8.51534 μM	SANGER
NTERA-S-cl-D1	Growth Inhibition Assay	IC50=20.4978 μM	SANGER
NUGC-3	Growth Inhibition Assay	IC50=10.4402 μM	SANGER
OAW-42	Growth Inhibition Assay	IC50=5.98821 μM	SANGER
OC-314	Growth Inhibition Assay	IC50=6.91159 μM	SANGER
OCI-AML2	Growth Inhibition Assay	IC50=17.5317 μM	SANGER
OMC-1	Growth Inhibition Assay	IC50=14.7888 μM	SANGER
ONS-76	Growth Inhibition Assay	IC50=4.24192 μM	SANGER
OS-RC-2	Growth Inhibition Assay	IC50=10.1045 μM	SANGER
OVCAR-4	Growth Inhibition Assay	IC50=10.7068 μM	SANGER
OVCAR-5	Growth Inhibition Assay	IC50=41.7767 μM	SANGER
P12-ICHIKAWA	Growth Inhibition Assay	IC50=24.6258 μM	SANGER
P30-OHK	Growth Inhibition Assay	IC50=46.8117 μM	SANGER
PA-1	Growth Inhibition Assay	IC50=1.82725 μM	SANGER
PC-3	Growth Inhibition Assay	IC50=27.8941 μM	SANGER
PFSK-1	Growth Inhibition Assay	IC50=12.9507 μM	SANGER
PSN1	Growth Inhibition Assay	IC50=21.6453 μM	SANGER
QIMR-WIL	Growth Inhibition Assay	IC50=12.8258 μM	SANGER
Ramos-2G6-4C10	Growth Inhibition Assay	IC50=11.932 μM	SANGER
RH-18	Growth Inhibition Assay	IC50=43.805 μM	SANGER
RMG-I	Growth Inhibition Assay	IC50=49.4444 μM	SANGER
RO82-W-1	Growth Inhibition Assay	IC50=11.9064 μM	SANGER
RPMI-2650	Growth Inhibition Assay	IC50=24.6162 μM	SANGER
RPMI-7951	Growth Inhibition Assay	IC50=13.5136 μM	SANGER
RPMI-8226	Growth Inhibition Assay	IC50=3.62616 μM	SANGER
RS4-11	Growth Inhibition Assay	IC50=24.142 μM	SANGER
RT-112	Growth Inhibition Assay	IC50=2.13424 μM	SANGER
S-117	Growth Inhibition Assay	IC50=6.50267 μM	SANGER
SBC-5	Growth Inhibition Assay	IC50=14.1362 μM	SANGER
SCC-15	Growth Inhibition Assay	IC50=10.4718 μM	SANGER
SCC-4	Growth Inhibition Assay	IC50=3.50396 μM	SANGER
SF126	Growth Inhibition Assay	IC50=3.30017 μM	SANGER
SF295	Growth Inhibition Assay	IC50=3.02597 μM	SANGER
SF539	Growth Inhibition Assay	IC50=26.8018 μM	SANGER
SiHa	Growth Inhibition Assay	IC50=13.8346 μM	SANGER
SJRH30	Growth Inhibition Assay	IC50=17.8489 μM	SANGER
SKG-IIIa	Growth Inhibition Assay	IC50=14.8001 μM	SANGER
SK-HEP-1	Growth Inhibition Assay	IC50=31.4271 μM	SANGER
SK-LMS-1	Growth Inhibition Assay	IC50=34.4107 μM	SANGER
SK-MEL-1	Growth Inhibition Assay	IC50=22.8368 μM	SANGER
SK-MEL-2	Growth Inhibition Assay	IC50=16.4485 μM	SANGER
SK-MEL-24	Growth Inhibition Assay	IC50=41.4725 μM	SANGER
SK-N-AS	Growth Inhibition Assay	IC50=25.8584 μM	SANGER
SK-N-DZ	Growth Inhibition Assay	IC50=26.049 μM	SANGER
SK-NEP-1	Growth Inhibition Assay	IC50=7.6961 μM	SANGER
SK-N-FI	Growth Inhibition Assay	IC50=7.63033 μM	SANGER
SK-OV-3	Growth Inhibition Assay	IC50=1.06633 μM	SANGER
SK-PN-DW	Growth Inhibition Assay	IC50=7.4815 μM	SANGER
SK-UT-1	Growth Inhibition Assay	IC50=16.565 μM	SANGER
SN12C	Growth Inhibition Assay	IC50=9.45234 μM	SANGER
SNB75	Growth Inhibition Assay	IC50=31.2435 μM	SANGER
SNU-387	Growth Inhibition Assay	IC50=32.3191 μM	SANGER
SNU-423	Growth Inhibition Assay	IC50=4.6079 μM	SANGER
SNU-449	Growth Inhibition Assay	IC50=7.01072 μM	SANGER
SNU-C2B	Growth Inhibition Assay	IC50=18.2276 μM	SANGER
SW1088	Growth Inhibition Assay	IC50=7.65826 μM	SANGER
SW1463	Growth Inhibition Assay	IC50=30.5383 μM	SANGER
SW1573	Growth Inhibition Assay	IC50=4.55163 μM	SANGER
SW1710	Growth Inhibition Assay	IC50=13.3641 μM	SANGER
SW48	Growth Inhibition Assay	IC50=27.8005 μM	SANGER
SW620	Growth Inhibition Assay	IC50=38.4974 μM	SANGER
SW756	Growth Inhibition Assay	IC50=0.99846 μM	SANGER
SW780	Growth Inhibition Assay	IC50=1.65158 μM	SANGER
SW948	Growth Inhibition Assay	IC50=19.3934 μM	SANGER
SW962	Growth Inhibition Assay	IC50=49.9332 μM	SANGER
SW982	Growth Inhibition Assay	IC50=3.33875 μM	SANGER
T-24	Growth Inhibition Assay	IC50=2.48037 μM	SANGER
T47D	Growth Inhibition Assay	IC50=10.155 μM	SANGER
T98G	Growth Inhibition Assay	IC50=9.90203 μM	SANGER
TE-1	Growth Inhibition Assay	IC50=8.44316 μM	SANGER
TE-11	Growth Inhibition Assay	IC50=8.99551 μM	SANGER
TGBC11TKB	Growth Inhibition Assay	IC50=9.02241 μM	SANGER
TGBC24TKB	Growth Inhibition Assay	IC50=24.0312 μM	SANGER
TI-73	Growth Inhibition Assay	IC50=22.3498 μM	SANGER
U-118-MG	Growth Inhibition Assay	IC50=28.0123 μM	SANGER
U251	Growth Inhibition Assay	IC50=46.994 μM	SANGER
U-2-OS	Growth Inhibition Assay	IC50=26.7382 μM	SANGER
UACC-257	Growth Inhibition Assay	IC50=1.82163 μM	SANGER
UMC-11	Growth Inhibition Assay	IC50=27.9343 μM	SANGER
UM-UC-3	Growth Inhibition Assay	IC50=23.1944 μM	SANGER
VA-ES-BJ	Growth Inhibition Assay	IC50=2.24957 μM	SANGER
VMRC-RCZ	Growth Inhibition Assay	IC50=14.5774 μM	SANGER
WM-115	Growth Inhibition Assay	IC50=27.7767 μM	SANGER
YAPC	Growth Inhibition Assay	IC50=24.8214 μM	SANGER
YH-13	Growth Inhibition Assay	IC50=2.21671 μM	SANGER
YKG-1	Growth Inhibition Assay	IC50=31.0263 μM	SANGER

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00692341	Hepatic Insufficiency	Phase 1	Completed	-	United States, Florida ... 展开 >> Pfizer Investigational Site Miami, Florida, United States, 33169 Pfizer Investigational Site Orlando, Florida, United States, 32809 收起 <<
NCT03386929	Non-small Cell Lung Cancer Met... 展开 >>astatic Non-Small Cell Lung Cancer Stage IIIB 收起 <<	Phase 1 Phase 2	Recruiting	December 2022	United States, California ... 展开 >> UCSD Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Sarah MOORE sam055@ucsd.edu Principal Investigator: Lyudmila BAZHENOVA, MD United States, South Dakota Avera Cancer Center Recruiting Sioux Falls, South Dakota, United States, 57105 Contact: Martha LANG Martha.lang@avera.org Principal Investigator: Benjamin SOLOMON, MD France Centre Léon Bérard Recruiting Lyon, France, 69008 Contact: Séverine LAURENT severine.laurent@lyon.unicancer.fr Principal Investigator: Pierre SAINTIGNY, MD Israel Chiam Sheba Medical Center Recruiting Ramat Gan, Israel, 5265601 Contact: Yona GILADY yona.gilady@sheba.health.gov.il Principal Investigator: Jair BAR, MD Luxembourg Centre Hospitalier Luxembourg Recruiting Luxembourg, Luxembourg, 1210 Contact: Lucile PERNOT lucile.pernot@lih.lu Principal Investigator: Guy BERCHEM, MD Spain Vall Hebron Institute of Oncology Recruiting Barcelona, Spain, 08035 Contact: LLuisa CARBONELL llcarbonell@vhio.net Principal Investigator: Enriqueta Felip, MD 收起 <<
NCT00389441	Thyroid Neoplasms	Phase 2	Completed	-	-
NCT00460603	Colorectal Neoplasms	Phase 1 Phase 2	Completed	-	-
NCT01469052	Advanced Solid Tumors	Phase 1	Completed	-	United States, California ... 展开 >> Pfizer Investigational Site San Francisco, California, United States, 94115 United States, Texas Pfizer Investigational Site Houston, Texas, United States, 77030 United States, Wisconsin Pfizer Investigational Site Madison, Wisconsin, United States, 53792 收起 <<
NCT00692341	-		Completed	-	-
NCT01469052	-		Completed	-	-
NCT02184416	-		Recruiting	July 20, 2019	-
NCT00389441	-		Completed	-	-
NCT00460603	-		Completed	-	-
NCT00600821	Non-Small-Cell Lung Carcinoma ... 展开 >> Adenocarcinoma 收起 <<	Phase 2	Completed	-	-
NCT00094055	Thyroid Neoplasms	Phase 2	Completed	-	United States, California ... 展开 >> Pfizer Investigational Site Santa Monica, California, United States, 90404 United States, Colorado Pfizer Investigational Site Aurora, Colorado, United States, 80010 Pfizer Investigational Site Denver, Colorado, United States, 80220 United States, Illinois Pfizer Investigational Site Chicago, Illinois, United States, 60637 United States, Maryland Pfizer Investigational Site Baltimore, Maryland, United States, 21231-1000 Pfizer Investigational Site Baltimore, Maryland, United States, 51231 United States, Michigan Pfizer Investigational Site Ann Arbor, Michigan, United States, 48109 United States, Pennsylvania Pfizer Investigational Site Philadelphia, Pennsylvania, United States, 19111 United States, Texas Pfizer Investigational Site Houston, Texas, United States, 77030-4009 收起 <<
NCT00094055	-		Completed	-	-
NCT00726752	Neoplasms	Phase 1	Completed	-	Japan ... 展开 >> Pfizer Investigational Site Kobe-shi, Hyogo-ken, Japan 收起 <<
NCT01020136	Healthy Volunteer	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT00726752	-		Completed	-	-
NCT03086174	Kidney Cancer Stage Iv ... 展开 >> Advanced Melanoma 收起 <<	Phase 1	Recruiting	February 2021	China, Beijing ... 展开 >> Beijing Cancer Hospital Recruiting Beijing, Beijing, China, 100142 Contact: Jun Guo, Phd; Md guoj307@126.com Principal Investigator: Jun Guo, PhD; MD Sub-Investigator: xinan Sheng, MD 收起 <<
NCT00094107	Melanoma Skin... 展开 >> Neoplasms 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Pfizer Investigational Site Orange, California, United States, 92868 United States, Florida Pfizer Investigational Site Miami Beach, Florida, United States, 33140 United States, Massachusetts Pfizer Investigational Site Boston, Massachusetts, United States, 02114 Pfizer Investigational Site Boston, Massachusetts, United States, 02115 Pfizer Investigational Site Boston, Massachusetts, United States, 02215 United States, Pennsylvania Pfizer Investigational Site Clairton, Pennsylvania, United States, 15025 Pfizer Investigational Site Greensburg, Pennsylvania, United States, 15601 Pfizer Investigational Site Johnstown, Pennsylvania, United States, 15901 Pfizer Investigational Site Pittsburgh, Pennsylvania, United States, 15232-1305 Pfizer Investigational Site Pittsburgh, Pennsylvania, United States, 15232 Pfizer Investigational Site Wexford, Pennsylvania, United States, 15090 France Pfizer Investigational Site Paris Cedex 13, France, 75651 收起 <<
NCT00600821	-		Completed	-	-
NCT00094107	-		Completed	-	-
NCT00219557	Pancreatic Neoplasms	Phase 2	Completed	-	-
NCT00918632	Healthy Volunteers	Phase 1	Completed	-	Belgium ... 展开 >> Pfizer Investigational Site Bruxelles, Belgium, 1070 收起 <<
NCT00071006	Acute Myeloid Leukemia (AML) ... 展开 >> Myelodysplastic Syndrome 收起 <<	Phase 2	Completed	-	United States, Texas ... 展开 >> Pfizer Investigational Site Houston, Texas, United States, 77030 收起 <<
NCT03538717	-		Recruiting	June 30, 2019	Spain ... 展开 >> Hospital Duran i Reynals Not yet recruiting Hospitalet de Llobregat, Barcelona, Spain, 08908 Hospital Universitario Parc Taulí Not yet recruiting Sabadell, Barcelona, Spain, 08208 Hospital Sant Pau i Santa Tecla Not yet recruiting Tarragona, Barcelona, Spain, 43003 Hospital Universitario Mutua Terrassa Not yet recruiting Terrassa, Barcelona, Spain, 08221 Complejo Hospitalario la Mancha Centro Not yet recruiting Alcazar de San Juan, Ciudad REAL, Spain, 13600 Hospital Universitario Principe de Asturias Not yet recruiting Alcalá de Henares, Madrid, Spain, 28805 Hospital Universitario Fundacion Alcorcón Recruiting Alcorcón, Madrid, Spain, 28922 Hospital Universitario Severo Ochoa Recruiting Leganés, Madrid, Spain, 28911 Hospital Universitario Rey Juan carlos Not yet recruiting Mostoles, Madrid, Spain, 28933 Hospital Infanta Cristina Not yet recruiting Parla, Madrid, Spain, 28981 Hospital Universitario Infanta Sofía Not yet recruiting San Sebatián De Los Reyes, Madrid, Spain, 28703 Hospital Universitario Infanta Elena Not yet recruiting Valdemoro, Madrid, Spain, 28342 Hospital Universitario Son Espases Not yet recruiting Palma de Mallorca, Mallorca, Spain, 07120 HU de Navarra, Pamplona Not yet recruiting Pamplona, Navarra, Spain, 31008 Hospital Universitario de Canarias Not yet recruiting La Cuesta, Santa Cruz De Tenerife, Tenerife, Spain, 38320 Hospital Universitario Nuestra Señora de la Candelaria, Tenerife Not yet recruiting Santa Cruz de Tenerife, Tenerife, Spain, 38010 Hospita General Nuestra Señora del Prado Not yet recruiting Talavera de la Reina, Toledo, Spain, 45600 Hospital del Mar Not yet recruiting Barcelona, Spain, 08003 Hospital Universitario Vall d'Hebrón Not yet recruiting Barcelona, Spain, 08036 HU Clinic i Provincial Not yet recruiting Barcelona, Spain, 08036 Hospital Universitario Sant Pau i Santa Creu Recruiting Barcelona, Spain, 08041 Hospital General Universitario de Ciudad Real Not yet recruiting Ciudad Real, Spain, 13005 Hospital Reina Sofía Not yet recruiting Córdoba, Spain, 14004 Hospital Universitario de Cabueñes Not yet recruiting Gijón, Spain, 33394 Complejo Hospitalario de Jaén Not yet recruiting Jaén, Spain, 23007 HU De León Not yet recruiting León, Spain, 24080 Hospital Universitario Lucus Augusti (HULA_ Lugo) Not yet recruiting Lugo, Spain, 27003 Hospital Universitario Ramón y Cajal Recruiting Madrid, Spain, 28034 Hospital Universitario Fundación Jimenez Diaz Not yet recruiting Madrid, Spain, 28040 Hospital Universitario 12 de Octubre Not yet recruiting Madrid, Spain, 28041 Hospital Universitario La Paz Not yet recruiting Madrid, Spain, 28046 Centro Integral Oncológico Clara Campal Not yet recruiting Madrid, Spain, 28050 Complejo Hospitalario Universitario de Ourense CHUOU Not yet recruiting Orense, Spain, 32005 Hospital Universitario Central de Asturias Not yet recruiting Oviedo, Spain, 33011 Hospital Universitario Santiago de Compostela Not yet recruiting Santiago de Compostela, Spain, 15076 Complejo Asistencial de Segovia Not yet recruiting Segovia, Spain, 40002 Hospita Virgen de la Salud de Toledo Not yet recruiting Toledo, Spain, 45004 Instituto Valenciano de Oncología Not yet recruiting Valencia, Spain, 46009 Hospital Clínico Universitario de Valencia Recruiting Valencia, Spain, 46010 Hospital Universitario y Politécnico La Fe Not yet recruiting Valencia, Spain, 46026 Hospital Universitario de Vigo- Hospital Álvaro Cunqueiro Recruiting Vigo, Spain, 36312 H. Universitario Miguel Servet, Zaragoza Not yet recruiting Zaragoza, Spain, 50009 Hospital Clínico Uiversitario Lozano Blesa Not yet recruiting Zaragoza, Spain, 50009 收起 <<
NCT01999972	Advanced Solid Tumors	Phase 1	Active, not recruiting	July 31, 2018	United States, Illinois ... 展开 >> University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Indiana Investigational Drug Services IUHSCC Indianapolis, Indiana, United States, 46202 IU Health University Hospital Indianapolis, Indiana, United States, 46202 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 United States, Michigan Wayne State University, Dept. of Oncology Detroit, Michigan, United States, 48201 United States, Minnesota University of Minnesota Health Clinics and Surgery Center Minneapolis, Minnesota, United States, 55455 University of Minnesota Medical Center, Fairview IDS Pharmacy Minneapolis, Minnesota, United States, 55455 University of Minnesota Medical Center, Fairview Minneapolis, Minnesota, United States, 55455 University of Minnesota Physicians Masonic Cancer Center Minneapolis, Minnesota, United States, 55455 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Utah Huntsman Cancer Hospital Salt Lake City, Utah, United States, 84112 Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 John A Moran Eye Center Salt Lake City, Utah, United States, 84132 United States, Wisconsin University Station Ophthalmology Clinic Madison, Wisconsin, United States, 53705 University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 United Kingdom St Bartholomew's Hospital - Barts Health NHS Trust London, United Kingdom, EC1A 7BE The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital London, United Kingdom, SW3 6JJ 收起 <<
NCT00768755	Carcinoma, Non-Small Cell Lung	Phase 1 Phase 2	Completed	-	-
NCT00219557	-		Completed	-	-
NCT00447005	Carcinoma	Phase 1	Completed	-	Japan ... 展开 >> Pfizer Investigational Site Kashiwa, Chiba, Japan 收起 <<
NCT00768755	-		Completed	-	-
NCT03172754	Renal Cell Carcinoma	Phase 1 Phase 2	Recruiting	April 2019	United States, Pennsylvania ... 展开 >> Fox Chase Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19111 Contact: Matthew Zibelman, MD 215-214-1515 matthew.zibelman@fccc.edu 收起 <<
NCT00735904	Carcinoma, Non-Small-Cell Lung... 展开 >> (NSCLC) 收起 <<	Phase 2	Completed	-	Poland ... 展开 >> Pfizer Investigational Site Torun, Poland, 87-100 Pfizer Investigational Site Wodzislaw Sl., Poland, 44-300 Romania Pfizer Investigational Site Cluj-Napoca, Cluj, Romania, 400015 Pfizer Investigational Site Bucuresti, Romania, 022328 Pfizer Investigational Site Oradea, Romania, 410032 South Africa Pfizer Investigational Site Parktown, South Africa, 2193 Ukraine Pfizer Investigational Site Dnipropetrovsk, Ukraine, 49102 Pfizer Investigational Site Donetsk, Ukraine, 83092 Pfizer Investigational Site Kyiv, Ukraine, 04107 Pfizer Investigational Site Lviv, Ukraine, 79031 收起 <<
NCT00735904	-		Completed	-	-
NCT02667886	Clear Cell Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 1 Phase 2	Active, not recruiting	-	-
NCT00071006	-		Completed	-	-
NCT01210495	Hepatocellular Carcinoma	Phase 2	Completed	-	-
NCT00282048	Kidney Neoplasms ... 展开 >> Carcinoma, Renal Cell 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> Pfizer Investigational Site Chicago, Illinois, United States, 60637 United States, New York Pfizer Investigational Site Bronx, New York, United States, 10466 United States, Ohio Pfizer Investigational Site Cleveland, Ohio, United States, 44195 United States, Pennsylvania Pfizer Investigational Site Philadelphia, Pennsylvania, United States, 19111-2497 United States, Wisconsin Pfizer Investigational Site Madison, Wisconsin, United States, 53792 收起 <<
NCT00569946	Carcinoma, Renal Cell	Phase 2	Completed	-	Japan ... 展开 >> Pfizer Investigational Site Kashiwa, Chiba, Japan Pfizer Investigational Site Sapporo, Hokkaido, Japan Pfizer Investigational Site Tsukuba, Ibaraki, Japan Pfizer Investigational Site Morioka, Iwate, Japan Pfizer Investigational Site Nankoku-shi, Kochi-ken, Japan Pfizer Investigational Site Osakasayama, Osaka, Japan Pfizer Investigational Site Hamamatsu-City, Shizuoka, Japan Pfizer Investigational Site Sunto-gun, Shizuoka, Japan Pfizer Investigational Site Arakawa-ku, Tokyo, Japan Pfizer Investigational Site Chuo-ku, Tokyo, Japan Pfizer Investigational Site Itabashi-ku, Tokyo, Japan Pfizer Investigational Site Akita, Japan Pfizer Investigational Site Fukuoka, Japan Pfizer Investigational Site Kyoto, Japan Pfizer Investigational Site Osaka, Japan Pfizer Investigational Site Tokushima, Japan Pfizer Investigational Site Yamagata, Japan 收起 <<
NCT00454649	Neoplasms	Phase 1	Completed	-	United States, Georgia ... 展开 >> Pfizer Investigational Site Augusta, Georgia, United States, 30909 Pfizer Investigational Site Augusta, Georgia, United States, 30912 United States, Illinois Pfizer Investigational Site Harvey, Illinois, United States, 60426-4265 Pfizer Investigational Site Harvey, Illinois, United States, 60426 Pfizer Investigational Site Tinley Park, Illinois, United States, 60477 United States, Indiana Pfizer Investigational Site Hobart, Indiana, United States, 46342 Pfizer Investigational Site Munster, Indiana, United States, 46321 United States, Pennsylvania Pfizer Investigational Site Philadelphia, Pennsylvania, United States, 19111 United States, Texas Pfizer Investigational Site Houston, Texas, United States, 77030-4009 United States, Washington Pfizer Investigational Site Kennewick, Washington, United States, 99336 Poland Pfizer Investigational Site Warszawa, Poland, 02-781 Spain Pfizer Investigational Site Barcelona, Spain, 08003 Pfizer Investigational Site Madrid, Spain, 28046 收起 <<
NCT00447005	-		Completed	-	-
NCT00094094	-		Completed	-	-
NCT00094094	Lung Neoplasms ... 展开 >> Carcinoma, Non-small Cell Lung 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Pfizer Investigational Site Irvine, California, United States, 92612 Pfizer Investigational Site Orange, California, United States, 92868 United States, Illinois Pfizer Investigational Site Chicago, Illinois, United States, 60637 Pfizer Investigational Site Park Ridge, Illinois, United States, 60068 United States, Minnesota Pfizer Investigational Site Coon Rapids, Minnesota, United States, 55433 Pfizer Investigational Site Fridley, Minnesota, United States, 55432 Pfizer Investigational Site Robbinsdale, Minnesota, United States, 55422 United States, North Carolina Pfizer Investigational Site Charlotte, North Carolina, United States, 28203 United States, Tennessee Pfizer Investigational Site Nashville, Tennessee, United States, 37232 United States, Wisconsin Pfizer Investigational Site Madison, Wisconsin, United States, 53792 Germany Pfizer Investigational Site Gauting, Germany, 82131 收起 <<
NCT01210495	-		Completed	-	-
NCT00282048	-		Completed	-	-
NCT00842244	Stomach Neoplasms ... 展开 >> Advanced Gastric Cancer 收起 <<	Phase 1	Completed	-	Japan ... 展开 >> Pfizer Investigational Site Kashiwa, Chiba, Japan Pfizer Investigational Site Yufu-city, Oita, Japan Korea, Republic of Pfizer Investigational Site Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769 Pfizer Investigational Site Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707 Pfizer Investigational Site Seoul, Korea, Republic of, 110-744 收起 <<
NCT00569946	-		Completed	-	-
NCT00842244	-		Completed	-	-
NCT01649180	-		Terminated(Closed due to prolo... 展开 >>nged enrollment timelines) 收起 <<	-	-
NCT02535533	Advanced Metastatic Clear Cell... 展开 >> Renal Cell Carcinoma (CCRCC) 收起 <<	Phase 1	Suspended(Suspended for interi... 展开 >>m analysis) 收起 <<	September 2020	United States, Iowa ... 展开 >> University of Iowa Hospitals and Clinics Iowa City, Iowa, United States, 52242 收起 <<
NCT01441414	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Terminated(See termination rea... 展开 >>son in detailed description.) 收起 <<	-	United States, Arizona ... 展开 >> Pinnacle Oncology Hematology Scottsdale, Arizona, United States, 85258 Arizona Oncology Associates, PC - HOPE Tucson, Arizona, United States, 85704 Arizona Oncology Associates, PC-HOPE Tucson, Arizona, United States, 85710 United States, Colorado Rocky Mountain Cancer Centers Aurora, Colorado, United States, 80012 Rocky Mountain Cancer Centers Boulder, Colorado, United States, 80303 Rocky Mountain Cancer Centers Centennial, Colorado, United States, 80112 Rocky Mountain Cancer Centers Colorado Springs, Colorado, United States, 80907 Rocky Mountain Cancer Centers Colorado Springs, Colorado, United States, 80909 Rocky Mountain Cancer Centers Denver, Colorado, United States, 80218 Rocky Mountain Cancer Centers Denver, Colorado, United States, 80220 Rocky Mountain Cancer Centers Lakewood, Colorado, United States, 80228 Rocky Mountain Cancer Centers Littleton, Colorado, United States, 80120-4413 Rocky Mountain Cancer Centers Lone Tree, Colorado, United States, 80124 Rocky Mountain Cancer Centers Longmont, Colorado, United States, 80501 Rocky Mountain Cancer Centers Parker, Colorado, United States, 80138 Rocky Mountain Cancer Centers Pueblo, Colorado, United States, 81008 Rocky Mountain Cancer Centers Thornton, Colorado, United States, 80260 United States, Nebraska Nebraska Methodist Hospital Omaha, Nebraska, United States, 68114 United States, Nevada Comprehensive Cancer Centers of Nevada Henderson, Nevada, United States, 89014 Comprehensive Cancer Centers of Nevada Henderson, Nevada, United States, 89052 Comprehensive Cancer Centers of Nevada Henderson, Nevada, United States, 89074 Comprehensive Cancer Centers of Nevada Las Vegas, Nevada, United States, 89128 Comprehensive Cancer Centers of Nevada Las Vegas, Nevada, United States, 89148 Comprehensive Cancer Centers of Nevada Las Vegas, Nevada, United States, 89169 United States, North Carolina Regional Cancer Care-Durham Durham, North Carolina, United States, 27704 United States, Texas Investigational Products Center (IPC) (drug shipment only) Fort Worth, Texas, United States, 76177 Texas Oncology-Tyler Tyler, Texas, United States, 75702 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 University of Washington Medical Center Seattle, Washington, United States, 98195 Czech Republic Masarykuv onkologicky ustav Brno, Czech Republic, 65653 收起 <<
NCT01441414	-		Terminated(See termination rea... 展开 >>son in detailed description.) 收起 <<	-	-
NCT01056263	-		Completed	-	United States, California ... 展开 >> Pfizer Investigational Site San Francisco, California, United States, 94115 United States, Massachusetts Pfizer Investigational Site Boston, Massachusetts, United States, 02114 Pfizer Investigational Site Boston, Massachusetts, United States, 02215 United States, New York Pfizer Investigational Site New York, New York, United States, 10065 United States, Ohio Pfizer Investigational Site Cleveland, Ohio, United States, 44195 United States, Wisconsin Pfizer Investigational Site Madison, Wisconsin, United States, 53792 France Pfizer Investigational Site Paris Cedex 13, France, 75651 Germany Pfizer Investigational Site Hannover, Germany, 30625 收起 <<
NCT01174238	Melanoma	Phase 2	Completed	-	United States, California ... 展开 >> Cutaneous Onocology Group at the Helen Dillar Family Comprehensive Cancer Center UCSF San Francisco, California, United States, 94115 收起 <<
NCT01056263	-		Completed	-	-
NCT01649180	Renal Cell Carcinoma	Phase 2	Terminated(Closed due to prolo... 展开 >>nged enrollment timelines) 收起 <<	-	United States, Nebraska ... 展开 >> Missouri Valley Cancer Consortium Omaha, Nebraska, United States, 68106 United States, Ohio Cleveland Clinic, Taussig Cancer Institute Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania, Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT00454649	-		Completed	-	-
NCT00905814	Healthy Volunteers	Phase 1	Completed	-	Singapore ... 展开 >> Pfizer Investigational Site Singapore, Singapore, 188770 收起 <<
NCT01540526	Solid Malignancies ... 展开 >> Metastatic Castrate-resistant Prostate Cancer 收起 <<	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> University of Wisconsin Carbone Cancer Center Madison, Wisconsin, United States, 53792 收起 <<
NCT01174238	-		Completed	-	-
NCT00920816	Kidney Neoplasms	Phase 3	Active, not recruiting	May 30, 2021	-
NCT01490866	-		Completed	-	-
NCT03736330	Renal Cancer Metastatic	Phase 2	Recruiting	November 8, 2021	China, Guangdong ... 展开 >> Cancer Center, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510060 Contact: Fang-Jian Zhou, M.D Ph.D zhoufj@sysucc.org.cn Contact: Zhi-Ling Zhang, M.D Ph.D zhangzhl@sysucc.org.cn Principal Investigator: Fang-Jian Zhou, M.D Ph.D Principal Investigator: Jian-Chuan Xia, Ph.D Sub-Investigator: Zhi-Ling Zhang, M.D Ph.D 收起 <<
NCT00828919	Solid Tumors	Not Applicable	Active, not recruiting	May 31, 2021	-
NCT00920816	-		Active, not recruiting	-	-
NCT00835978	Carcinoma, Renal Cell	Phase 2	Completed	-	-
NCT01967576	Pheochromocytoma ... 展开 >> Paraganglioma 收起 <<	Phase 2	Active, not recruiting	December 1, 2019	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT02853331	Renal Cell Carcinoma	Phase 3	Active, not recruiting	January 27, 2020	-
NCT01490866	Colorectal Cancer	Phase 2	Completed	-	United States, Arkansas ... 展开 >> NEA Baptist Clinic Jonesboro, Arkansas, United States, 72401 United States, Florida Florida Cancer Specialists-South Fort Myers, Florida, United States, 33916 Woodlands Medical Specialists Pensacola, Florida, United States, 32503 Florida Cancer Specialists-North St. Petersburg, Florida, United States, 33705 United States, Georgia Northeast Georgia Medical Center Gainesville, Georgia, United States, 30501 United States, Indiana Oncology Hematology of SW Indiana Newburgh, Indiana, United States, 47630 Hope Cancer Center Terre Haute, Indiana, United States, 47802 United States, Michigan Grand Rapids Oncology Program Grand Rapids, Michigan, United States, 49503 United States, Nebraska Nebraska Methodist Hospital Omaha, Nebraska, United States, 68114 United States, New Jersey Atlantic Health System Summit, New Jersey, United States, 07901 United States, Tennessee Tennessee Oncology Nashville, Tennessee, United States, 37203 United States, Texas Texas Health Physician Group Dallas, Texas, United States, 75243 收起 <<
NCT01334073	Malignant Advanced Solid Tumor... 展开 >>s Carcinoma, Renal Cell 收起 <<	Phase 1	Completed	-	France ... 展开 >> Professeur Alain RAVAUD Bordeaux, France, 33000 Professeur Jean-Pierre DELORD Toulouse, France, 31000 收起 <<
NCT00835978	-		Completed	-	-
NCT00678392	Kidney Neoplasms	Phase 3	Completed	-	-
NCT01385059	Stage III Prostate Cancer ... 展开 >> Stage IV Prostate Cancer 收起 <<	Phase 2	Active, not recruiting	November 2019	United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010 收起 <<
NCT00678392	-		Completed	-	-
NCT01352728	Hepatocellular Carcinoma	Phase 2	Completed	-	Hong Kong ... 展开 >> Department of Clinical Oncology, Prince of Wales Hospital Hong Kong, Hong Kong 收起 <<
NCT02133742	Renal Cell Carcinoma	Phase 1	Active, not recruiting	February 2019	United States, District of Col... 展开 >>umbia Georgetown University Medical Center Washington, District of Columbia, United States, 20007 United States, Florida H. Lee Moffitt Cancer Center & Research Institute, Inc. Tampa, Florida, United States, 33612 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Brigham & Women's Hospital Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Drug Shipment Address: Attn. Alicia Sammarco, RPh, NYU Investigational Pharmacy New York, New York, United States, 10016 NYU Langone Medical Center New York, New York, United States, 10016 NYU Langone New York, New York, United States, 10016 United States, Ohio Investigational Drug Services (Drug Management Only) Columbus, Ohio, United States, 43210 James Cancer Hospital Columbus, Ohio, United States, 43210 The James Cancer Hospital Columbus, Ohio, United States, 43210 Martha Morehouse Medical Plaza Columbus, Ohio, United States, 43221 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Henry-Joyce Cancer Clinic Nashville, Tennessee, United States, 37232 United States, Texas Texas Oncology - Baylor Charles A. Sammons Cancer Center Dallas, Texas, United States, 75246 收起 <<
NCT00919204	Healthy Volunteers	Phase 1	Completed	-	China ... 展开 >> Pfizer Investigational Site Beijng, China, 100730 收起 <<
NCT02636725	Alveolar Soft Part Sarcoma ... 展开 >> Soft Tissue Sarcomas 收起 <<	Phase 2	Recruiting	March 2019	United States, Florida ... 展开 >> University of Miami Recruiting Miami, Florida, United States, 33136 Contact: Breelyn Wilky, MD 305-243-1287 b.wilky@med.miami.edu Principal Investigator: Breelyn Wilky, MD Sub-Investigator: Jonathan Trent, MD 收起 <<
NCT01486251	Colorectal Carcinoma	Not Applicable	Completed	-	France ... 展开 >> Institut gustave roussy Villejuif, France, 94805 收起 <<
NCT03092856	Clear Cell Renal Cell Carcinom... 展开 >>a Metastatic Renal Cell Cancer Recurrent Renal Cell Carcinoma Stage IV Renal Cell Cancer 收起 <<	Phase 2	Recruiting	July 19, 2021	United States, California ... 展开 >> USC / Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Sarmad Sadeghi, MD 323-865-0553 sarmad.sadeghi@usc.edu Principal Investigator: Sarmad Sadeghi University of California Davis Comprehensive Cancer Center Not yet recruiting Sacramento, California, United States, 95817 Contact: Primo N. Lara 916-734-3089 Principal Investigator: Primo N. Lara United States, Ohio Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Not yet recruiting Cleveland, Ohio, United States, 44195 Contact: Brian I. Rini 866-223-8100 Principal Investigator: Brian I. Rini Ohio State University Comprehensive Cancer Center Not yet recruiting Columbus, Ohio, United States, 43210 Contact: Amir Mortazavi 614-293-6196 Principal Investigator: Amir Mortazavi United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Not yet recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Rahul A. Parikh 412-647-8073 parikhr@upmc.edu Principal Investigator: Rahul A. Parikh 收起 <<
NCT02156895	-		Recruiting	August 21, 2021	Korea, Republic of ... 展开 >> Pfizer Tower Recruiting Seoul, Korea, Republic of, 04631 收起 <<
NCT01529138	Cancer	Phase 1	Completed	-	United States, Georgia ... 展开 >> Emory University Winship Cancer Institute Atlanta, Georgia, United States, 30322 收起 <<
NCT01473043	-		-	-	Australia, Queensland ... 展开 >> Pfizer Investigational Site Douglas, Queensland, Australia, 4814 Australia, Tasmania Pfizer Investigational Site Hobart, Tasmania, Australia, 7000 Australia, Victoria Pfizer Investigational Site Wendouree, Victoria, Australia, 3355 Canada, Quebec Pfizer Investigational Site Montreal, Quebec, Canada, H2X 1N8 收起 <<
NCT01249547	Recurrent or Metastatic NPC	Phase 2	Completed	-	Hong Kong ... 展开 >> Department of Clinical Oncology, Prince of Wales Hospital Hong Kong, Hong Kong 收起 <<
NCT01483638	Colorectal Carcinoma	Phase 2	Terminated(The trial was prema... 展开 >>turely closed due to lack of accrual) 收起 <<	-	Spain ... 展开 >> Spanish Cooperative Group for Digestive Tumour Therapy Madrid, Spain, 28046 收起 <<
NCT01255137	Adrenal Cortex Neoplasms	Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT03289533	Carcinoma, Hepatocellular	Phase 1	Recruiting	October 7, 2019	Japan ... 展开 >> Aichi Cancer Center Hospital Recruiting Nagoya, Aichi, Japan, 464-8681 Iizuka Hospital Active, not recruiting Iizuka, Fukuoka, Japan, 820-8505 Kindai University Hospital, Department of Gastroenterology and Hepatology Active, not recruiting Osaka-Sayama, Osaka, Japan, 589-8511 National Cancer Center Hospital Recruiting Chuo-ku, Tokyo, Japan, 104-0045 Kyorin University Hospital, Department of Medical Oncology Active, not recruiting Mitaka-shi, Tokyo, Japan, 181-8611 Japanese Red Cross Musashino Hospital Active, not recruiting Musashino, Tokyo, Japan, 180-8610 National Hospital Organization Kyushu Medical Center Recruiting Fukuoka, Japan, 810-8563 收起 <<
NCT01255137	-		Completed	-	-
NCT01321437	Melanoma Mali... 展开 >>gnant Melanoma Stage IIIA Melanoma Stage IIIB Melanoma Stage IIIC Melanoma 收起 <<	Phase 2	Active, not recruiting	December 2019	United States, California ... 展开 >> Chao Family Comprehensive Cancer Center Orange, California, United States, 92868 收起 <<
NCT03595124	Metastatic Renal Cell Carcinom... 展开 >>a Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions Stage III Renal Cell Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 TFE3 Gene Translocation TFEB Gene Translocation 收起 <<	Phase 2	Recruiting	June 18, 2023	-
NCT01409200	Prostate Cancer	Phase 2	Active, not recruiting	February 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01508117	-		Terminated(transferred study s... 展开 >>ponsor) 收起 <<	-	-
NCT01508117	Glioblastoma Multiforme	Phase 2	Terminated(transferred study s... 展开 >>ponsor) 收起 <<	-	United States, Ohio ... 展开 >> University of Cincinnati Cincinnati, Ohio, United States, 45267-0502 收起 <<
NCT01727336	Advanced Renal Cell Carcinoma	Phase 2	Active, not recruiting	December 2018	-
NCT01744249	Neuroendocrine Tumors ... 展开 >> Advanced Cancer 收起 <<	Phase 2 Phase 3	Recruiting	October 2020	Germany ... 展开 >> Berlin Charité Universitätsmedizin Recruiting Berlin, Germany Principal Investigator: Frank-Ulrich Pape, Dr. Marburg Universitätsklinikum Giessen und Marburg GmbH Recruiting Marburg, Germany, 35043 Principal Investigator: Anja Rinke, Dr. Klinikum rechts der Isar Recruiting München, Germany, 81675 Principal Investigator: Alexander Von Werder, Dr. Italy Azienda Ospedaliera Universitaria di Perugia Recruiting Perugia, Italy, 06129 Principal Investigator: Vicenzo Minotti, Dr. Sapienza, Universitá di Roma, Ospedale sant'Andrea Recruiting Rome, Italy, 00189 Principal Investigator: Francesco Panzuto, Dr. Spain Hospital Central de Asturias Recruiting Oviedo, Asturias, Spain Principal Investigator: Paula Jiménez Fonseca, MD Institut Català d'Oncologia L'Hospitalet Recruiting L'Hospitalet de Llobregat, Barcelona, Spain Principal Investigator: Alexandre Teulé, MD Hospital Universitario Virgen de la Victoria Recruiting Málaga, Malaga, Spain, 29010 Principal Investigator: Isabel Sevilla, MD Hospital Alvaro Cunqueiro Recruiting Vigo, Pontevedra, Spain, 36312 Principal Investigator: M. José Villanueva Silva, MD Complejo Hospitalario Univ A Coruña Recruiting A Coruña, Spain Principal Investigator: Luis antón Aparicio, MD Sub-Investigator: María Quindós, MD Hospital Universitari Vall d'Hebron Recruiting Barcelona, Spain Principal Investigator: Jaume Capdevila, MD Hospital Universitario de Burgos Recruiting Burgos, Spain Contact: Guillermo Crespo Herrero, MD Principal Investigator: Guillermo Crespo Herrero, MD Hospital Virgen de las Nieves Recruiting Granada, Spain Principal Investigator: Encarnación González Flores, MD Hospital universitario de Leon Suspended Leon, Spain MD Anderson Cancer Center Recruiting Madrid, Spain, 28033 Principal Investigator: Enrique Grande Pulido, MD Hospital Clara Campal Suspended Madrid, Spain Hospital Clínico San Carlos Recruiting Madrid, Spain Principal Investigator: Javier Sastre Hospital Gregorio Marañón Recruiting Madrid, Spain Principal Investigator: Pilar García Alfonso, MD Hospital Univ La Paz Recruiting Madrid, Spain Principal Investigator: Ana Custodio, MD Hospital Universitario 12 de Octubre Recruiting Madrid, Spain Principal Investigator: Daniel Castellano, MD Hospital Universitario Ramón y Cajal Recruiting Madrid, Spain Principal Investigator: Teresa Alonso Gordoa, MD Hospital Univ de Salamanca Recruiting Salamanca, Spain Principal Investigator: Miguel Navarro, MD Hospital de Donostia Recruiting San Sebastian, Spain Principal Investigator: Adelaida La Casta, MD Sub-Investigator: Sara Arévalo, MD Hospital Marqués de Valdecilla Recruiting Santander, Spain Principal Investigator: Carlos López, MD Hospital Universitario Virgen del Rocío Recruiting Sevilla, Spain Principal Investigator: Marta Benavent, MD Hospital General Universitario de Valencia Recruiting Valencia, Spain, 46014 Principal Investigator: Vega Iranzo, MD Hospital La Fe Withdrawn Valencia, Spain Hospital Universitario Miguel Servet Recruiting Zaragoza, Spain Contact: Vicente Alonso, M.D. Principal Investigator: Vicente Alonso, M.D. United Kingdom Clatterbridge Cancer Centre Suspended Bebington, Wirral, United Kingdom, CH63 4JY Queen Elisabeth Hospital Birmingham Not yet recruiting Birmingham, United Kingdom, B15 2TH Principal Investigator: Tahir Shah, Dr. Royal Free Hospital Recruiting London, United Kingdom, NW3 2QG Principal Investigator: Christine Thirlwell, Prof. Christie NHS Foundation Trust Not yet recruiting Manchester, United Kingdom, MB204BX Principal Investigator: Juan Valle, Prof. 收起 <<
NCT02684006	Renal Cell Cancer	Phase 3	Active, not recruiting	April 30, 2021	-
NCT03291314	Recurrent Glioblastoma (WHO-Gr... 展开 >>ade IV Glioma) 收起 <<	Phase 2	Recruiting	September 30, 2018	Belgium ... 展开 >> UZ Brussel Recruiting Brussel, Belgium, 1090 Contact: Bart Neyns, Phd,Md +32 2 477 ext 54 47 bart.neyns@uzbrussel.be Principal Investigator: Bart Neyns, Phd,Md 收起 <<
NCT02762513	Squamous Cell Carcinoma of the... 展开 >> Head and Neck 收起 <<	Phase 2	Recruiting	November 2020	United States, Michigan ... 展开 >> University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Cancer Answer Line 800-865-1125 Principal Investigator: Francis Worden, M.D. 收起 <<
NCT01273662	Hepatocellular Carcinoma	Phase 2	Completed	-	Taiwan ... 展开 >> National Taiwan University Hospital Taipei City, Taiwan, 100 Taipei Veterans General Hospital Taipei City, Taiwan, 11217 Tri-Service General Hospital Taipei City, Taiwan, 114 收起 <<
NCT01469546	Head and Neck Squamous Cell Ca... 展开 >>rcinoma 收起 <<	Phase 2	Completed	-	United States, Michigan ... 展开 >> University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 收起 <<
NCT01140737	Soft Tissue Sarcoma	Phase 2	Active, not recruiting	December 2018	United Kingdom ... 展开 >> Aberdeen Royal Infirmary Aberdeen, Scotland, United Kingdom Western General Hospital Edinburgh, Scotland, United Kingdom Bristol Haematology & Oncology Centre Bristol, United Kingdom St. James's Hospital Leeds, United Kingdom Royal Marsden Hospital London, United Kingdom Royal Marsden London, United Kingdom University College London Hospitals London, United Kingdom Christies Manchester, United Kingdom Nottingham City Hospital Nottingham, United Kingdom Churchill Hospital Oxford, United Kingdom Penella Woll Sheffield, United Kingdom Southampton General Hospital Southampton, United Kingdom Clatterbridge Centre for Oncology Wirral, United Kingdom 收起 <<
NCT01469546	-		Completed	-	-
NCT00859118	Neoplasms	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53575 收起 <<
NCT01798446	Renal Cell Carcinoma ... 展开 >> Nonclear Cell Temsirolimus Resistance 收起 <<	Phase 2	Unknown	December 2016	Korea, Republic of ... 展开 >> Seou National University Hospital Recruiting Seoul, Korea, Republic of, 110744 Contact: Se-Hoon Lee, MD, PhD 82220722199 shlee119@snu.ac.kr Principal Investigator: Se-Hoon Lee, MD, PhD Sub-Investigator: Dae Seog Heo, MD, PhD Sub-Investigator: Dong-Wan Kim, MD, PhD Sub-Investigator: Tae Min Kim, MD, PhD Sub-Investigator: Bhumsuk Keam, MD 收起 <<
NCT01211275	Malignant Pleural Mesothelioma	Phase 1 Phase 2	Completed	-	Netherlands ... 展开 >> Antoni van Leeuwenhoekziekenhuis (NKI-AVL) Amsterdam, Noord-Holland, Netherlands, 1066 CX 收起 <<
NCT01558661	-		Completed	-	-
NCT01263769	Kidney Cancer	Phase 2	Active, not recruiting	February 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01599754	Clear Cell Renal Carcinoma	Phase 3	Terminated(Primary endpoint di... 展开 >>d not reach statistical significance) 收起 <<	-	-
NCT02493751	Renal Cell Cancer	Phase 1	Active, not recruiting	January 22, 2020	United States, Arizona ... 展开 >> Oncology Research Associates, PLLC d/b/a Pinnacle Oncology Hematology Scottsdale, Arizona, United States, 85258 United States, District of Columbia Georgetown University Medical Center Department of Pharmacy, Research Washington, District of Columbia, United States, 20007 Georgetown University Medical Center Washington, District of Columbia, United States, 20007 United States, Massachusetts Brigham & Women's Hospital Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Drug Shipment address: Attn. Alicia Sammarco, RPh,NYU Investigational Pharmacy New York, New York, United States, 10016 Laura & Isaac Perlmutter Cancer Center At NYU Langone New York, New York, United States, 10016 NYU Langone Medical Center New York, New York, United States, 10016 United States, Ohio Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44106 Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Tennessee Henry Joyce Cancer Clinic Nashville, Tennessee, United States, 37232-5310 Vanderbilt University Oncology Pharmacy (ship drug only) Nashville, Tennessee, United States, 37232 United States, Utah University of Utah, Huntsman Cancer Hospital Salt Lake City, Utah, United States, 84112 University of Utah, Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Japan Niigata University Medical & Dental Hospital Chuo-ku, Niigata, Niigata, Japan, 951-8520 Kindai University Hospital Osakasayama, Osaka, Japan, 589-8511 Keio University Hospital Shinjuku-ku, Tokyo, Japan, 160-8582 United Kingdom Mount Vernon Cancer Center, East and North Herts. NHS Trust London, Middlesex, United Kingdom, HA6 2RN St Helier Hospital Carshalton, Surrey, United Kingdom, SM5 1AA St. Bartholomew's Hospital London, United Kingdom, EC1A 7BE The Royal Marsden NHS Foundation Trust London, United Kingdom, SW3 6JJ The Christie NHS Foundation Trust Manchester, United Kingdom, M20 4BX The Royal Marsden NHS Foundation Trust Sutton, United Kingdom, SM2 5PT 收起 <<
NCT03341845	Renal Cell Carcinoma	Phase 2	Recruiting	January 31, 2025	Netherlands ... 展开 >> Antoni van Leeuwenhoek Recruiting Amsterdam, Netherlands, 1066CX Contact: Axel Bex, MD, PhD 0205129111 a.bex@nki.nl 收起 <<
NCT01533948	Extraocular Extension Melanoma... 展开 >> Metastatic Intraocular Melanoma Recurrent Intraocular Melanoma Recurrent Melanoma Stage IIIA Intraocular Melanoma Stage IIIA Melanoma Stage IIIB Intraocular Melanoma Stage IIIB Melanoma Stage IIIC Intraocular Melanoma Stage IIIC Melanoma Stage IV Intraocular Melanoma Stage IV Melanoma 收起 <<	Phase 2	Terminated(low accrual)	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 收起 <<
NCT01558661	Adenoid Cystic Carcinoma	Phase 2	Completed	-	United States, New York ... 展开 >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01533948	-		Terminated(low accrual)	-	-
NCT01806064	Renal Cell Carcinoma	Phase 1 Phase 2	Active, not recruiting	June 2019	-
NCT01435122	Carcinoid Tumor	Phase 2	Completed	-	United States, California ... 展开 >> University of California San Francisco (UCSF) San Francisco, California, United States, 94115 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT02639182	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Active, not recruiting	January 2019	-
NCT01435122	-		Completed	-	-
NCT01334112	Hepatocellular Carcinoma	Phase 2	Completed	-	Canada, Alberta ... 展开 >> Foothills Hospital, Alberta Health Services Calgary, Alberta, Canada Canada, Ontario University Health Network, Princess Margaret Hospital Toronto, Ontario, Canada 收起 <<
NCT02859012	Recurrent ACC, metastaticACC, ... 展开 >>Unreaectable ACC 收起 <<	Phase 2	Active, not recruiting	August 2020	Korea, Republic of ... 展开 >> Department of Internal Medicine, Seoul National University Hospital Seoul, Korea, Republic of, 110-744 收起 <<
NCT03472560	Non-Small Cell Lung Cancer ... 展开 >> Urothelial Cancer 收起 <<	Phase 2	Recruiting	September 18, 2020	United States, Arizona ... 展开 >> Arizona Oncology Associates- Saguaro Cancer Center Recruiting Glendale, Arizona, United States, 85308 Arizona Oncology Associates- Biltmore Cancer Center Recruiting Phoenix, Arizona, United States, 85016 Arizona Oncology Associates- Deer Valley Cancer Center Recruiting Phoenix, Arizona, United States, 85027 Arizona Oncology Associates- East Valley Cancer Center Recruiting Tempe, Arizona, United States, 85284 United States, Michigan Karmanos Cancer Institute Not yet recruiting Detroit, Michigan, United States, 48201 Karmanos Cancer Institute Not yet recruiting Farmington Hills, Michigan, United States, 48334 United States, Missouri Oncology Hematology Associates Recruiting Springfield, Missouri, United States, 65807 United States, Nebraska Oncology Hematology West, PC dba Nebraska Cancer Specialists Recruiting Omaha, Nebraska, United States, 68114 Oncology Hematology West, PC dba Nebraska Cancer Specialists Recruiting Omaha, Nebraska, United States, 68130 United States, Ohio Toledo Clinic Cancer Center- Toledo Not yet recruiting Toledo, Ohio, United States, 43623 United States, South Carolina Saint Francis Hospital Recruiting Greenville, South Carolina, United States, 29601 Saint Francis Hospital Cancer Center Recruiting Greenville, South Carolina, United States, 29607 Hungary Orszagos Onkologiai Intezet Not yet recruiting Budapest, Hungary, H-1122 Pecsi Tudomanyegyetem Klinikai Kozpont Not yet recruiting Pecs, Hungary, H-7624 Tudogyogyintezet Torokbalint Recruiting Torokbalint, Hungary, H-2045 Korea, Republic of National Cancer Center Recruiting Goyang-si, Gyeonggi-do, Korea, Republic of, 10408 Samsung Medical Center Recruiting Gangnam-gu, Seoul, Korea, Republic of, 06351 Asan Medical Center Not yet recruiting Songpa-gu, Seoul, Korea, Republic of, 05505 Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of, 03722 Taiwan Chi Mei Hospital, Liouying Recruiting Tainan City, Liouying District, Taiwan, 73657 National Cheng Kung University Hospital Not yet recruiting Tainan, Taiwan, 704 收起 <<
NCT02579811	Metastatic Renal Cell Cancer	Phase 2	Active, not recruiting	September 2019	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 United States, Ohio Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus, Ohio, United States, 43210 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232 收起 <<
NCT02782403	Leukemia	Phase 1 Phase 2	Recruiting	March 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact pbose@mdanderson.org 收起 <<
NCT02597322	cT2a N0NxM0 Renal Tumor	Phase 2	Completed	-	France ... 展开 >> Bicêtre Hospital Le Kremlin Bicêtre, France, 94275 收起 <<
NCT01693822	Clear-cell Metastatic Renal Ce... 展开 >>ll Carcinoma 收起 <<	Phase 2	Unknown	September 2016	United Kingdom ... 展开 >> Royal Marsden Hospital - sutton Recruiting London, Sutton, United Kingdom, SM2 5PT Principal Investigator: James Larkin, Dr Addenbrooke's Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Principal Investigator: Timothy Eisen, Prof Royal Marsden Hospital Recruiting London, United Kingdom, SW3 6JJ Principal Investigator: James Larkin, Dr Christie Hospital Recruiting Manchester, United Kingdom, M20 4BX Principal Investigator: Robert Hawkins, Prof Derriford Hospital Recruiting Plymouth, United Kingdom, PL6 8DH Principal Investigator: Martin Highley, Dr Royal Surrey County Hospital Recruiting Surrey, United Kingdom, GU2 7XX Principal Investigator: Agnieszka Michael, Dr 收起 <<
NCT01562197	Glioblastoma Multiforme	Phase 2	Active, not recruiting	December 2017	Belgium ... 展开 >> UZ Brussel Brussel, Belgium, 1090 收起 <<
NCT02489695	Papillary Renal Cell Carcinoma	Phase 2	Active, not recruiting	January 2019	France ... 展开 >> ICO Paul Papin Angers, France, 49933 Chu Bordeaux Bordeaux, France, 33075 Centre Francois Baclesse Caen, France, 14076 Centre Geogres François Leclerc Dijon, France, 21079 Centre Leon Berard Lyon, France, 69373 Institut Paoli Calmettes Marseille, France, 13273 ICO - René Gauducheau Saint-herblain, France, 44805 Institut Claudius Regaud Toulouse, France, 31059 ICL Vandoeuvre-les-nancy, France, 54519 Gustave Roussy Villejuif, France, 94805 收起 <<
NCT02261207	Solitary Fibrous Tumor	Phase 2	Unknown	March 2018	Italy ... 展开 >> Fondazione IRCCS Istituto Naazionale dei Tumori Not yet recruiting Milan, MI, Italy, 20133 Contact: Silvia Stacchiotti, MD +39 022390 ext 2807 silvia.stacchiotti@istitutotumori.mi.it Principal Investigator: Silvia Stacchiotti, MD 收起 <<
NCT02164838	Refractory or Recurrent Solid ... 展开 >>Tumors, Excluding CNS Tumors 收起 <<	Phase 1	Completed	-	-
NCT02700568	Carcinoma, Renal Cell ... 展开 >> Clear Cell Renal Cell Carcinoma 收起 <<	Phase 2	Recruiting	August 2018	Russian Federation ... 展开 >> Demchenkova Marina Viktorovna Recruiting Irkutsk, Russian Federation Semenov Andrey Vladimirovich Recruiting Ivanovo, Russian Federation Mikhailova Nadezhda Vasilievna Recruiting Kazan, Russian Federation Eskerov Kurban Abdulmutalibovich Active, not recruiting Kirov, Russian Federation Zukov Ruslan Aleksandrovich Recruiting Krasnoyarsk, Russian Federation Ovchinnikova Elena Georgievna Recruiting Nizhny Novgorod, Russian Federation Guseva Irina Vasilievna Recruiting Penza, Russian Federation Vladimirova Lyubov Yur'evna Active, not recruiting Rostov-on-Don, Russian Federation Zolotoreva Tatiana Gennadievna Recruiting Samara, Russian Federation Katkov Alexey Aleksandrovich Active, not recruiting Saratov, Russian Federation Ivannikov Andrey Andreyevich Recruiting Tambov, Russian Federation Usynin Evgeny Anatolievich Recruiting Tomsk, Russian Federation Evstegneyeva Irina Vladimirovna Recruiting Tver, Russian Federation Khmelevsky Andrey Anatolievich Recruiting Ufa, Russian Federation Gurina Ludmila Ivanovna Active, not recruiting Vladivostok, Russian Federation 收起 <<
NCT03592199	Clear Cell Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Recruiting	December 11, 2022	Brazil ... 展开 >> Instituto do Cancer do Estado de São Paulo Recruiting São Paulo, Brazil, 01246000 Contact: David QB Muniz, MD +551138932691 david.muniz@hc.fm.usp.br Contact: Diogo A Bastos, MD +551138932691 diogo.bastos@hc.fm.usp.br Principal Investigator: David QB Muniz, MD Sub-Investigator: Carlos Dzik, MD, PHD Sub-Investigator: Diogo A Bastos, MD Sub-Investigator: Jamile A Silva, MD Sub-Investigator: Pedro HI Velho, MD 收起 <<
NCT02857712	Salivary Gland Cancers	Phase 2	Active, not recruiting	June 2019	Italy ... 展开 >> Fondazione IRCCS Istituto Nazionale dei Tumori Milan, Italy, 20133 收起 <<
NCT03494816	Renal Cell Carcinoma ... 展开 >> Metastatic Renal Cell Carcinoma Non-metastatic Renal Cell Carcinoma 收起 <<	Phase 2	Recruiting	June 1, 2020	United Kingdom ... 展开 >> Addenbrookes Hospital Recruiting Cambridge, United Kingdom, CB2 0QQ Contact: Ellie Couch Principal Investigator: Kate Fife Western General Hospital Recruiting Edinburgh, United Kingdom, EH4 2XU Contact: Susan Forman Principal Investigator: Steve Leung Beatson West of Scotland Cancer Centre Recruiting Glasgow, United Kingdom, G12 0YN Contact: Maria Nicol Principal Investigator: Rob Jones St George's Hospital Not yet recruiting London, United Kingdom, SW17 0QT Contact: Sam Hollingworth Principal Investigator: Pieter Le Roux Royal Marsden Recruiting London, United Kingdom, SW3 6JJ Contact: Darshana Shah Principal Investigator: David Nicol The Christie Not yet recruiting Manchester, United Kingdom, M20 4BX Contact: Kate Armitage Principal Investigator: Tom Waddell 收起 <<
NCT02129647	Neurofibromatosis Type 2 ... 展开 >> Vestibular Schwannomas 收起 <<	Phase 2	Recruiting	January 2019	United States, New York ... 展开 >> NYU Langone Medical Center Recruiting New York, New York, United States, 10016 Contact: Srivandana Akshintala, MD 212-263-8400 Srivandana.Akshintala@nyumc.org Principal Investigator: Srivandana A Akshintala, MD Sub-Investigator: Jeffrey Allen, MD Sub-Investigator: Katharine McNeill, MD 收起 <<
NCT02814461	Advanced Hepatocellular Carcin... 展开 >>oma (HCC) 收起 <<	Phase 1	Recruiting	November 2018	Taiwan ... 展开 >> Shin Kong Wu Ho-Su Memorial Hospital Recruiting Taipei, Taiwan, 11101 Contact: Kai-Lin Yang, M.D. +886-28332211 ext 2275 M011360@ms.skh.org.tw 收起 <<
NCT03438708	Clear Cell Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Recruiting	February 1, 2020	United States, California ... 展开 >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Candace M Winkler, MS 858-822-5398 cmwinkler@ucsd.edu Contact: Arlene Araneta 8588226187 aaraneta@ucsd.edu 收起 <<

阿昔替尼 /Axitinib 98%

Axitinib 纯度/质量文件

全球学术期刊中引用的产品

Axitinib 生物活性

Axitinib 细胞研究

Axitinib 动物研究

Axitinib 临床研究

Axitinib 参考文献

Axitinib 实验方案

Axitinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

阿昔替尼 /Axitinib 98%

Axitinib 纯度/质量文件

全球学术期刊中引用的产品

Axitinib 生物活性

Axitinib 细胞研究

Axitinib 动物研究

Axitinib 临床研究

Axitinib 参考文献

Axitinib 实验方案

Axitinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z